Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study

Published:2017-03-08 Issue:7 Volume:28 Page:606-612
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Ara-Martín Mariano¹,Pinto Pedro Herranz²,Pascual-Salcedo Dora³

Affiliation:

1. Servicio de Dermatología, Hospital Clínico Lozano Blesa, Zaragoza, Spain;

2. Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain;

3. Immunology Unit, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, Spain

Funder

Pfizer

Novartis

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2017.1296927

Reference34 articles.

1. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

2. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

3. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

4. Etanercept as Monotherapy in Patients with Psoriasis

5. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence;Autoimmunity Reviews;2024-04

2. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22

3. Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2;Journal of the European Academy of Dermatology and Venereology;2023-07-28

4. TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy;Science Immunology;2021-11-26

5. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis;Clinics;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3